ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Boehringer licenses Yuhan’s NASH drug

by Lisa M. Jarvis
July 5, 2019 | APPEARED IN VOLUME 97, ISSUE 27

 

Boehringer Ingelheim will pay South Korea’s Yuhan $40 million to jointly develop a treatment for nonalcoholic steatohepatitis (NASH) and related liver diseases. Companies are developing numerous therapies to treat NASH, a serious liver disorder marked by fat accumulation, inflammation, and scarring. While most treatments in development address one of those three traits, Yuhan’s molecule, a dual agonist of GLP-1 and FGF21, aims to address both inflammation and scarring.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment